| 0.6962 0.015 (2.22%) | 12-05 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.81 | 1-year : | 0.95 |
| Resists | First : | 0.69 | Second : | 0.81 |
| Pivot price | 0.66  |
|||
| Supports | First : | 0.63 |
Second : | 0.58 |
| MAs | MA(5) : | 0.68 |
MA(20) : | 0.66 |
| MA(100) : | 0.78 |
MA(250) : | 0.88 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 85.4 |
| RSI | RSI(14): 51 |
|||
| 52-week | High : | 1.49 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ONTX ] has closed below upper band by 40.6%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.71 |
| Low: | 0.65 - 0.66 | 0.66 - 0.66 |
| Close: | 0.67 - 0.67 | 0.67 - 0.68 |
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Fri, 17 Nov 2023
Onconova Therapeutics Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Thu, 16 Nov 2023
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcript - Yahoo Finance
Thu, 02 Nov 2023
Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL - Onconova Therapeutics (NASDAQ:ONTX) - Benzinga
Thu, 28 Sep 2023
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress - Yahoo Finance
Sun, 13 Aug 2023
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript - Yahoo Finance
Mon, 17 Jul 2023
Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 2.085e+007 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 65 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.155e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 928 % |
| Return on Equity (ttm) | -38.1 % |
| Qtrly Rev. Growth | 226000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -49.3 |
| EBITDA (p.s.) | 132164 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.66 |
| Dividend | 0 |
| Forward Dividend | 85520 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|